Study of SD-101 for epidermolysis bullosa in children
Part of Genetic & congenital, Skin clinical trials.
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 28 days and 12 years old.
- Your child has been diagnosed with simplex, recessive dystrophic, or intermediate junctional EB.
- Your child has at least one wound that is 10 to 50 square centimeters (about the size of a credit card to a small hand) and has been present for at least 21 days.
- The total skin affected by wounds is at least 5% of their body surface area.
- Your child has not used certain treatments (like steroids, antibiotics, or other investigational drugs) within the past month.
- Your child does not have a current or past cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a follow-up safety study for people who have already completed an earlier trial of SD-101 for epidermolysis bullosa (a condition causing fragile skin). It aims to check the long-term safety of the treatment.
This trial tests a new cream that may help heal wounds in people with epidermolysis bullosa (EB), a condition causing fragile skin that blisters easily. The cream is applied directly to the wounds, and researchers will compare two similar wounds on the same person to see if the cream works better than a cream without the medicine.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
This study evaluates pz-cel, a personalized skin cell treatment for wounds caused by dystrophic epidermolysis bullosa (a genetic condition causing fragile skin). It provides access to the treatment when the manufactured product doesn't meet standard release, or for patients needing special access, and helps ensure its safety and effectiveness.
This study tests an investigational drug called efgartigimod, which may help reduce harmful antibodies that attack the skin in certain blistering diseases. It is designed for people with dystrophic epidermolysis bullosa (DEB) or epidermolysis bullosa acquisita (EBA) who have antibodies against collagen VII.
This study tests an experimental eye drop (KB803) to see if it can reduce painful scrapes on the surface of the eye in people with dystrophic epidermolysis bullosa. You would be randomly assigned to receive either the study drops or a placebo (an inactive drop) for several months.
Hear when a new Epidermolysis Bullosa (EB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.